Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society · 2025
Feasibility of multiple-breath washout in the clinical setting and prediction of its duration in children and adults with cystic fibrosis.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Allomba Christine, Busack Leonie, Ziegahn Niklas, Pioch Charlotte O, Schnorr Alexandra N, Fuhlrott Bent R, Steinke Eva, Mall Marcus A, Stahl Mirjam
Аннотация
BACKGROUND: Pulmonary function tests play an important role in diagnosis, management and treatment of people with cystic fibrosis (pwCF). Multiple-breath washout (MBW) is a sensitive method to detect ventilation inhomogeneities and is established in children with CF. Despite promising data in adults with pulmonary diseases, its feasibility remains questioned in adults due to longer examination times and limited added value over spirometry. We aimed to analyse feasibility of MBW in pwCF and healthy controls (HC) and evaluate factors influencing test duration.
METHODS: We analysed 1,395 MBW measurements from pwCF (n = 1,158) and HC (n = 237). PwCF were divided according to percent predicted forced expiratory volume in one second (ppFEV1; high, >90 %; mid, 40-90 %; low, <40 %) and age groups. Test feasibility was defined as two acceptable trials. The impact of constitutional and disease severity factors was analysed.
RESULTS: Test feasibility was 100.0 % in HC and 94.3 % in pwCF, with higher feasibility in children than adults (96.0 % vs. 92.5 %, p = 0.01), and in those pwCF with higher ppFEV1 (high, 96.6 %; mid, 94.9 %; low, 82.6 %; p < 0.001). The higher the ppFEV1, the larger is the influence of constitutional factors over the impact of disease severity on trial time. Mean single trial time was 2.0 min, 2.7 min respectively 5.2 min in high, mid and low ppFEV1.
CONCLUSION: This study suggests extending MBW to adults with CF. Despite concerns about time efficiency, this study shows a good feasibility of MBW (92.5 %) in adults. Based on correlating factors, this study provides a decision-making tool for clinicians forecasting trial time.
METHODS: We analysed 1,395 MBW measurements from pwCF (n = 1,158) and HC (n = 237). PwCF were divided according to percent predicted forced expiratory volume in one second (ppFEV1; high, >90 %; mid, 40-90 %; low, <40 %) and age groups. Test feasibility was defined as two acceptable trials. The impact of constitutional and disease severity factors was analysed.
RESULTS: Test feasibility was 100.0 % in HC and 94.3 % in pwCF, with higher feasibility in children than adults (96.0 % vs. 92.5 %, p = 0.01), and in those pwCF with higher ppFEV1 (high, 96.6 %; mid, 94.9 %; low, 82.6 %; p < 0.001). The higher the ppFEV1, the larger is the influence of constitutional factors over the impact of disease severity on trial time. Mean single trial time was 2.0 min, 2.7 min respectively 5.2 min in high, mid and low ppFEV1.
CONCLUSION: This study suggests extending MBW to adults with CF. Despite concerns about time efficiency, this study shows a good feasibility of MBW (92.5 %) in adults. Based on correlating factors, this study provides a decision-making tool for clinicians forecasting trial time.